Skip to main content
SpringerLink
Log in

Controversies in Determination of Epoetin (Recombinant Human Erythropoietin) Dosages

  • Leading Article
  • Published:
Clinical Pharmacokinetics Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  • Abraham PA, Macres MG. Blood pressure in hemodialysis patients during amelioration of anemia with erythropoietin. Journal of the American Society of Nephrology 2: 927–936, 1991

    PubMed  CAS  Google Scholar 

  • Ad Hoc Committee for the National Kidney Foundation. Statement on the clinical use of recombinant erythropoietin in anemia of end-stage renal disease. American Journal of Kidney Diseases 14: 163–169, 1989

    Google Scholar 

  • Ballal SH, Domoto DT, Polack DC, Marciulonis P, Martin KJ. Androgens potentiate the effects of erythropoietin in the treatment of anemia of end-stage renal disease. American Journal of Kidney Diseases 17: 29–33, 1991

    PubMed  CAS  Google Scholar 

  • Bommer J, Barth H-P, Zeier M, Mandelbaum A, Bommer G, et al. Efficacy comparison of intravenous and subcutaneous recombinant human erythropoietin administration in hemodialysis patients. Contributions to Nephrology 88: 136–143, 1991

    PubMed  CAS  Google Scholar 

  • Bommer J, Ritz E, Weinreich TH, Bommer G, Ziegler T. Subcutaneous erythropoietin. Lancet 2: 406, 1988

    Article  PubMed  CAS  Google Scholar 

  • Buckner FS, Eschbach JW, Haley NR, Davidson RC, Adamson JW. Hypertension following erythropoietin therapy in anemic hemodialysis patients. American Journal of Hypertension 3: 947–955, 1990

    PubMed  CAS  Google Scholar 

  • Canadian Erythropoietin Study Group. Effect of recombinant human erythropoietin therapy on blood pressure in hemodialysis patients. American Journal of Nephrology 11: 23–26, 1991

    Article  Google Scholar 

  • Casati S, Passerini P, Campise MR, Graziani G, Cesana B, et al. Benefits and risks of protracted treatment with human recombinant erythropoietin in patients having haemodialysis. British Medical Journal 295: 1017–1020, 1987

    Article  PubMed  CAS  Google Scholar 

  • Cotes PM, Pippard MJ, Reid CDL, Winearls CG, Oliver DO, et al. Characterisation of the anaemia of chronic renal failure and the mode of its correction by a preparation of human erythropoietin (r-HuEPO): an investigation of the pharmacokinetics of intravenous erythropoietin and its effects on erythrokinetics. Quarterly Journal of Medicine 70 (New Series): 113–137, 1989

    PubMed  CAS  Google Scholar 

  • Duff DR, Golper TA, Sloan RS, Brier ME, Aronoff GR. Low-dose recombinant human erythropoietin therapy in chronic hemodialysis patients. American Journal of Kidney Diseases 18: 60–64, 1991

    PubMed  CAS  Google Scholar 

  • Erslev AJ. Erythropoietin. New England Journal of Medicine 324: 1339–1362, 1991

    Article  PubMed  CAS  Google Scholar 

  • Eschbach JW, Abdulhadi MH, Browne JK, Delano BG, Downing MR, et al. Recombinant human erythropoietin in anemic patients with end-stage renal disease: results of a phase III multicenter clinical trial. Annals of Internal Medicine 111: 992–1000, 1989a

    PubMed  CAS  Google Scholar 

  • Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin: results of a combined phase I and II clinical trial. New England Journal of Medicine 316: 73–78, 1987

    Article  PubMed  CAS  Google Scholar 

  • Eschbach JW, Kelly MR, Haley NR, Abels RI, Adamson JW. Treatment of the anemia of progressive renal failure with recombinant human erythropoietin. New England Journal of Medicine 321: 158–163, 1989b

    Article  PubMed  CAS  Google Scholar 

  • Fischl M, Galpin JE, Levine JD, Groopman JE, Henry DH, et al. Recombinant human erythropoietin for patients with AIDS treated with zidovudine. New England Journal of Medicine 322: 1488–1493, 1990

    Article  PubMed  CAS  Google Scholar 

  • Frenken LAM, Coppens PJW, Tiggeler RGWL, Koene RAP. Intraperitoneal erythropoietin. Lancet 2: 1495, 1988

    Article  PubMed  CAS  Google Scholar 

  • Granolleras C, Branger B, Beau MC, Deschodt G, Alsabadani B, et al. Experience with daily self-administered subcutaneous erythropoietin. Contributions to Nephrology 76: 143–148, 1989

    PubMed  CAS  Google Scholar 

  • Granolleras C, Branger B, Deschodt G, Shaldon S, Nonnast-Daniel B, et al. Two years experience of daily self-administered subcutaneous erythropoietin. Blood Purification 8: 268–271, 1990

    Article  PubMed  CAS  Google Scholar 

  • Granolleras C, Branger B, Shaldon S, Nonnast-Daniel B, Koch KM, et al. Subcutaneous erythropoietin: a comparison of daily and thrice weekly administration. Contributions to Nephrology 88: 144–148, 1991a

    PubMed  CAS  Google Scholar 

  • Granolleras C, Leskopf W, Shaldon S, Fourcade J. Experience of pain after subcutaneous administration of different preparations of recombinant human erythropoietin: a randomized double-blind crossover study. Clinical Nephrology 36: 294–298, 1991b

    PubMed  CAS  Google Scholar 

  • Halstenson CE, Macres M, Katz SA, Schnieder JR, Watanabe M, et al. Comparative pharmacokinetics and pharmacodynamics of epoetin alfa and beta. Clinical Pharmacology and Therapeutics 50: 702–712, 1991

    Article  PubMed  CAS  Google Scholar 

  • Held PJ, Levin NW, Bovbjerg RR, Pauly MV, Diamond LH. Mortality and duration of hemodialysis treatment. Journal of the American Medical Association 265: 871–875, 1991

    Article  PubMed  CAS  Google Scholar 

  • Kooistra MP, Struyvenberg A, van Es A. The response to recombinant human erythropoietin in patients with the anemia of end-stage renal disease is correlated with serum carnitine levels. Nephron 57: 127–128, 1991

    Article  PubMed  CAS  Google Scholar 

  • Kromer G, Soif A, Ehmer B, Kaufmann B, Quellhorst E. Single dose pharmacokinetics of recombinant human erythropoietin (rh EPO) comparing intravenous (iv), subcutaneous (sc) and intraperitoneal (ip) administration in IPD patients. Abstract. Kidney International 37: 331, 1990

    Google Scholar 

  • Levine SD, Dressler R, Lynn RI. Red blood cell life span (RBCTau) is a major determinant of the hematocrit (Hct) response to erythropoietin (Epo). Abstract no. 27P. Journal of the American Society of Nephrology 1: 401, 1990

    Google Scholar 

  • Lim VS, DeGowin RL, Zavala D, Kirchner PT, Abels R, et al. Recombinant human erythropoietin treatment in pre-dialysis patients: a double-blind placebo-controlled trial. Annals of Internal Medicine 110: 108–114, 1989

    PubMed  CAS  Google Scholar 

  • Lui SF, Chung WWM, Leung CB, Chan K, Lai KN. Pharmacokinetics and pharmacodynamics of subcutaneous and intraperitoneal administration of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis. Clinical Nephrology 33: 47–51, 1990

    PubMed  CAS  Google Scholar 

  • Lui SF, Law CB, Ting SM, Li P, Lai KN. Once weekly versus twice weekly subcutaneous administration of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis. Clinical Nephrology 36: 246–251, 1991

    PubMed  CAS  Google Scholar 

  • Macdougall IC, Hutton RD, Cavill I, Coles GA, Williams JD. Treating renal anaemia with recombinant human erythropoietin: practical guidelines and a clinical algorithm. British Medical Journal 300: 655–661, 1990

    Article  PubMed  CAS  Google Scholar 

  • Macdougall IC, Jones JM, Robinson MI, Miles JB, Coles GA, et al. Subcutaneous erythropoietin therapy: comparison of three different sites of injection. Contributions to Nephrology 88: 152–156, 1991b

    PubMed  CAS  Google Scholar 

  • Macdougall IC, Roberts DE, Coles GA, Williams JD. Clinical pharmacokinetics of epoetin (recombinant human erythropoietin). Clinical Pharmacokinetics 20: 99–113, 1991a

    Article  PubMed  CAS  Google Scholar 

  • McMahon LP, Dawborn JK. Experience with low dose intravenous and subcutaneous administration of recombinant human erythropoietin. American Journal of Nephrology 10: 404–408, 1990

    Article  PubMed  CAS  Google Scholar 

  • Nasu T, Shinohara Y, Mitsui H, Hayashida S. Treatment with recombinant human erythropoietin of renal anemia in CAPD patients: comparison of intraperitoneal and intravenous routes. Abstract. Journal of the American Society of Nephrology 1: 404, 1990

    Google Scholar 

  • Neff MS, Goldberg J, Slifkin RF, Eiser AR, Calamia V, et al. A comparison of androgens for anemia in patients on hemodialysis. New England Journal of Medicine 304: 871–875, 1981

    Article  PubMed  CAS  Google Scholar 

  • Piraino B, Johnston JR. The use of subcutaneous erythropoietin in CAPD patients. Clinical Nephrology 33: 200–202, 1990

    PubMed  CAS  Google Scholar 

  • Radtke HW, Frei U, Erbes PM, Schoeppe W, Koch KM. Improving anemia by hemodialysis: effect on serum erythropoietin. Kidney International 17: 382–387, 1980

    Article  PubMed  CAS  Google Scholar 

  • Raine AEG. Hypertension, blood viscosity, and cardiovascular morbidity in renal failure: implications of erythropoietin therapy. Lancet 1: 97–100, 1988

    Article  PubMed  CAS  Google Scholar 

  • Salmonson T, Danielson BG, Grahnen A, Wikstrom B. Pharmacokinetics of intravenous recombinant human erythropoietin in patients with chronic renal failure. Journal of Internal Medicine 228: 53–57, 1990

    Article  PubMed  CAS  Google Scholar 

  • Santiago GC, Rao TKS, Laird NM. Effect of dialysis therapy on the hematopoietic system: the national cooperative dialysis study. Kidney International 23 (Suppl. 13): S95–S100, 1983

    Google Scholar 

  • Shaldon S, Cotes M, Goldwasser E, Kampf D, Koch KM, et al. Does exogenous erythropoietin down-regulate endogenous erythropoietin? Contributions to Nephrology 88: 215–235, 1991

    Google Scholar 

  • Sisk JE, Gianfrancesco FD, Coster JM. Recombinant erythropoietin and Medicare payment. Journal of the American Medical Association 266: 247–252, 1991

    Article  PubMed  CAS  Google Scholar 

  • Slingeneyer A, Faller B, Laroche B, Ehmer B, Mion C. Self-administered daily subcutaneous recombinant human erythropoietin: an open randomized dose-finding study in ESRD patients receiving peritoneal dialysis. Contributions to Nephrology 88: 159–168, 1991

    PubMed  CAS  Google Scholar 

  • Sobota JT. Recombinant human erythropoietin in patients with anemia due to endstage renal disease: US multicenter trials. Contributions to Nephrology 76: 166–178, 1989

    PubMed  CAS  Google Scholar 

  • Stockenhuber F, Loibl U, Gottsauner-Wolf M, Jahn C, Manker W, et al. Pharmacokinetics and dose response after intravenous and subcutaneous administration of recombinant erythropoietin in patients on regular haemodialysis treatment or continuous ambulatory peritoneal dialysis. Nephron 59: 399–402, 1991

    Article  PubMed  CAS  Google Scholar 

  • Sundal E, Kaeser U. Correction of anaemia of chronic renal failure with recombinant human erythropoietin: safety and efficacy of one year’s treatment in a European multicentre study of 150 haemodialysis-dependent patients. Nephrology Dialysis and Transplantation 4: 979–987, 1989

    CAS  Google Scholar 

  • Uehlinger DE, Gotch FA. A pharmacodynamic model of erythropoietin therapy for uremic anemia. Abstract no. 68P. Journal of the American Society of Nephrology 1: 324, 1990

    Google Scholar 

  • Van Wyck DB, Stivelman JC, Ruiz J, Kirlin LF, Katz MA, et al. Iron status in patients receiving erythropoietin for dialysis-associated anemia. Kidney International 35: 712–716, 1989

    Article  PubMed  Google Scholar 

  • Winearls CG, Oliver DO, Pippard MJ, Reid C, Downing MR, et al. Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis. Lancet 2: 1175–1178, 1986

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The Drug Evaluation Unit, Division of Nephrology, Hennepin County Medical Center and University of Minnesota, Minneapolis, Minnesota, USA

    Paul A. Abraham, Wendy L. St Peter, Kimberly A. Redic-Kill & Charles E. Halstenson

Authors
  1. Paul A. Abraham
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Wendy L. St Peter
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kimberly A. Redic-Kill
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Charles E. Halstenson
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Abraham, P.A., St Peter, W.L., Redic-Kill, K.A. et al. Controversies in Determination of Epoetin (Recombinant Human Erythropoietin) Dosages. Clin. Pharmacokinet. 22, 409–415 (1992). https://doi.org/10.2165/00003088-199222060-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003088-199222060-00001

Keywords

Search

Navigation